Drugs / 13-cis-retinoic acid
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03611595 | Aug 2018 → Feb 2026 | cancer | Peter Zage | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03291080 | Apr 2018 → Sep 2019 | neuroblastoma | Nova Laboratories Limited | Completed | No outcome recorded |
| Phase 210 trials · 2 missed | ||||||
| Phase 2 | NCT05077813 | Dec 2021 → Feb 2022 | tuberculosis | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT04578236 | Nov → Dec 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 2 | NCT03323801 | Jul 2017 → May 2019 | azoospermia | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT02061384 | Aug 2014 → Dec 2018 | Klinefelter syndrome, partial chromosome Y deletion | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT01183884 | Aug 2010 → Nov 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01276730 | Oct 2007 → Aug 2015 | cervical cancer | University of Louisville | Completed | Missed primary |
| Phase 2 | NCT00528437 | Oct 2005 → Jun 2017 | brain neoplasm | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00062010 | May 2004 → May 2011 | small cell lung carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00000621 | Sep 1999 → Dec 2004 | pulmonary emphysema | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00002586 | Jan 1993 → Dec 2005 | lung cancer, poisoning | University of Colorado, Denver | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT05016349 | Aug → Oct 2021 | female breast carcinoma | Mahmoud Ramadan mohamed Elkazzaz | Unknown | No outcome recorded |
| Phase 3 | NCT03370367 | May 1989 → Jan 1999 | head and neck carcinoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05002530 | Nov → Dec 2021 | anosmia | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT04623385 | Nov → Dec 2020 | COVID-19 | Kafrelsheikh University | Unknown | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT05373901 Background | Jun 2022 → Jun 2023 | neuroblastoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT01183429 Background | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183897 Background | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01183416 Background | Aug 2010 → Oct 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00969722 Comparator | Aug 2009 → Aug 2010 | neuroblastoma | United Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00808899 Background | Dec 2008 → Jul 2009 | neuroblastoma | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00135135 Background | Aug 2005 → Jun 2007 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-cis-retinoic acid | “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗26“Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ “13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy” NCT01276730 ↗ “A study demonstrated that 13- cis -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.” NCT04578236 ↗ “A study demonstrated that 13- cis -Retinoic acid competitively and reversibly inhibits dihydrotestosterone.” NCT04623385 ↗ “13-cis-retinoic acid 160 mg/m2/day divided into two equal doses given orally BID x 14 days” NCT00135135 ↗ “13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols.” PMID 33919763 ↗ Apr 2021 “13-cis-retinoic acid is started no later than after cycle 4” NCT01183897 ↗ |
| Known as | 13-cis RA | “We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without alpha tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled...” PMID 19401528 ↗ Apr 2009 |
| Known as | 13-CRA | “13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols.” PMID 33919763 ↗ Apr 2021 |
| Known as | cRA | “Retinoid treatment arms were all-trans retinoic acid (ATRA trademark, Roche Laboratories, Inc.) at two different doses and 13-cis retinoic acid (cRA, Roche Laboratories, Inc.),...” NCT00000621 ↗ |
| Action | Inhibit | “13- cis -Retinoic acid will downregulate TMPRSS2 expression” NCT04578236 ↗ |
| Route | Oral | “Patients receive oral 13-cis retinoic acid daily.” NCT00002586 ↗ |
| Target | TMPRSS2 | “13- cis -Retinoic acid will downregulate TMPRSS2 expression thorough temporary preventing the effect of dihydrotestosterone (DHT) on the activation of TMPRSS2 gene expression.” NCT04578236 ↗ |